Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants

被引:64
作者
Esposito, S
Pugni, L
Bosis, S
Proto, A
Cesati, L
Bianchi, C
Cimino, C
Mosca, F
Principi, N
机构
[1] Univ Milan, Inst Pediat, I-20122 Milan, Italy
[2] Univ Milan, Dept Neonatol, Milan, Italy
[3] Wyeth Lederle Vaccines, Rome, Italy
关键词
Streptococcus pneumoniae; pneumococcal conjugate vaccine; pre-term infants;
D O I
10.1016/j.vaccine.2004.09.029
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We assessed the immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine (PCV7) administered three, five and 11 months post-natally to 46 pre-term (PT) and 46 full-term (FT) infants. After each dose, there was no significant difference between the groups in antibody levels for any of the vaccine serotypes. After the second dose, the majority of subjects in both groups showed titres of greater than or equal to0.35 mug/mL. whereas an antibody concentration of greater than or equal to 1.0 mug/mL was usually reached in both PT and FT infants after the third dose. Safety and tolerability was also similar in the groups. These findings support the use of the simplified schedule that includes three doses of PCV7 in both PT and FT infants, and suggest that this may reduce costs, as well as problems related to vaccine supply and administration (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1703 / 1708
页数:6
相关论文
共 30 条
  • [1] *AM AC PED, 2003, RED BOOK 2003 REP CO, P66
  • [2] [Anonymous], MMWR
  • [3] Safety and efficacy of the seven-valent pneumococcal conjugate vaccine: evidence from Northern California
    Black, S
    Shinefield, H
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2002, 161 (Suppl 2) : S127 - S131
  • [4] Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
    Black, S
    Shinefield, H
    Fireman, B
    Lewis, E
    Ray, P
    Hansen, JR
    Elvin, L
    Ensor, KM
    Hackell, J
    Siber, G
    Malinoski, F
    Madore, D
    Chang, I
    Kohberger, R
    Watson, W
    Austrian, R
    Edwards, K
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) : 187 - 195
  • [5] *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P1234
  • [6] *CDCP, 2002, JAMA-J AM MED ASSOC, V287, P833
  • [7] *CDCP, 2004, MMWR-MORBID MORTAL W, V53, P108
  • [8] Efficacy of a pneumococcal conjugate vaccine against acute otitis media
    Eskola, J
    Kilpi, T
    Palmu, A
    Jokinen, J
    Haapakoski, J
    Herva, E
    Takala, A
    Käyhty, H
    Karma, P
    Kohberger, R
    Siber, G
    Mäkela, PH
    Lockhart, S
    Ecrola, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (06) : 403 - 409
  • [9] Serum concentrations of pneumococcal anticapsular antibodies in children with pneumonia associated with Streptococcus pneumonia infection
    Esposito, S
    Droghetti, R
    Faelli, N
    Lastrico, A
    Tagliabue, C
    Cesati, L
    Bianchi, C
    Principi, N
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) : 1261 - 1264
  • [10] Theoretic coverage of heptavalent pneumococcal conjugate vaccine in the prevention of community-acquired pneumonia in children in Italy
    Esposito, S
    Madore, DV
    Gironi, S
    Bosis, S
    Tosi, S
    Bianchi, C
    Cimino, C
    Principi, N
    [J]. VACCINE, 2003, 21 (21-22) : 2704 - 2707